News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
A few sectors have dominated the market this year, and healthcare isn’t one of them. Many stocks in the sector look ready to gain. Continue Reading
SpaceX stock sinks after earnings. AMD drops after Elon Musk says his AI and space company will exclusively use Nvidia chips. Continue Reading
CVS Health (CVS) is collaborating with Eli Lilly (LLY) as part of enhancements to its direct-to-cons PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …
What happened: Eli Lilly (LLY) stock jumped as much as 7% on Wednesday. What's behind the move: The drug company raised its 2026 sales forecast after it saw strong demand for GLP-1 drugs in its fiscal second quarter. Revenue is now expected to fall …
This article first appeared on GuruFocus. Eli Lilly and Company (NYSE:LLY) rose 5.12% in premarket trading after posting second-quarter revenue of $22.97 billion, up 48% and well clear of the $20.69 billion analyst estimate. Non-GAAP earnings landed at $8.38 a share against a $6.01 …
This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind several leading diabetes and obesity treatments, reported second-quarter earnings and revenue well above Wall Street estimates as demand for Zepbound and Mounjaro continued to surge. Warning! GuruFocus has …
Eli Lilly stock jumped Wednesday on a solid beat-and-raise thanks to its GLP-1 drugs, treatments for diabetes and obesity. Continue Reading
Worldwide sales of weight loss and diabetes jab Mounjaro have doubled this year as demand continues to boom, drugmaker Eli Lilly has revealed. The manufacturer said its obesity medications Mounjaro and Zepbound were driving an acceleration of its overall sales. Mounjaro sales totalled 18.6 …
Eli Lilly (LLY) came out with quarterly earnings of $8.38 per share, beating the Zacks Consensus Estimate of $6.01 per share. This compares to earnings of $6.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …
CVS Health stock jumped on Wednesday after the healthcare giant raised its full-year guidance on the back of second-quarter earnings that handily beat analysts’ projections. For the second quarter, CVS Health posted adjusted earnings of $2.58 a share. Analysts polled by FactSet were looking …
Eli Lilly posted a blockbuster second quarter fueled by continued demand for its portfolio of GLP-1 medications. The world’s biggest drugmaker by market value reported adjusted earnings of $8.38 a share in the period, better than the $6.01 consensus estimate among analysts polled by …
Investing.com -- Eli Lilly shares jumped more than 5% in premarket trading Wednesday after the U.S. pharma giant raised its annual revenue guidance amid strong demand for its popular weight-loss and diabetes drugs. The company lifted its full-year 2026 revenue guidance to $85 billion …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Eli Lilly (LLY) stock is back in focus after the FDA granted Breakthrough Therapy designation to its investigational drug olomorasib for KRAS G12C-mutant advanced …
This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) will give a limited number of patients access to retatrutide, its experimental obesity drug, before U.S. approval, the company said. A spokesperson said it is "medically appropriate to make authentic retatrutide available before FDA approval," …
Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …
HIGHLIGHTS Amplia has executed a Clinical Trial Collaboration & Supply Agreement (CTCSA) with Eli Lilly & Company, to evaluate the Company's investigational FAK inhibitor narmafotinib in combination with Lilly's late‑stage investigational next generation KRAS inhibitor olomorasib The collaboration is underpinned by narmafotinib's growing base …
(Bloomberg) -- Wall Street's appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant's stock as primed for a split. Most Read from Bloomberg Beer …
This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) secured another regulatory boost for olomorasib after the FDA granted breakthrough therapy designation to the experimental drug as a standalone treatment for previously treated, advanced pancreatic cancer carrying the KRAS G12C mutation. The decision could …
As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines. Continue Reading
INDIANAPOLIS, Aug. 3, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have …
Key Takeaways; Cannabis Sector Vireo Growth to Acquire Planet 13 in Landmark All-Stock Deal SNDL Completed Parallel Asset Acquisition, Expanding its U.S. Medical Cannabis Footprint Tilray Posted Record FY2026 Revenue as Cannabis Sales Rose and Losses Narrowed Key Takeaways; Psychedelic Sector Eli Lilly's $3.8 …
President Trump said he's holding off on massive new Iran attacks. SpaceX, AMD, Sandisk, Lilly earnings loom as market rally attempt begins. Continue Reading
In another heavy earnings week, we’ll also see reports from McDonald’s, Disney, Uber, Devon Energy, and more. Continue Reading
President Trump said he's holding off on massive new Iran attacks. SpaceX, AMD, Sandisk, Lilly earnings loom as market rally attempt begins. Continue Reading
We are past the halfway mark of the Q2 earnings season, with more than 60% of S&P 500 companies having already reported. With another 27% of the index on deck this week, we will have seen the bulk of Q2 earnings by Friday. While …
The stock market bounced but hasn't taken this step while a key risk is growing. SpaceX, AMD, Sandisk, Eli Lilly earnings loom. Continue Reading
Wall Street analysts expect Eli Lilly (LLY) to post quarterly earnings of $6.71 per share in its upcoming report, which indicates a year-over-year increase of 6.3%. Revenues are expected to be $20.26 billion, up 30.2% from the year-ago quarter. Over the past 30 days, …
Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this drugmaker have returned -4.9% over the …
Round brings total capital raised to over $240 Million. BOSTON, July 31, 2026 /PRNewswire/ -- Ratio Therapeutics, Inc. (Ratio), a clinical-stage pharmaceutical company developing best-in-class radiopharmaceuticals for cancer treatment, today announced the closing of a $70 million Series C financing.Ratio Therapeutics The financing included …
This blockbuster class of drugs is shattering all sales records. Which stock will do better—Eli Lilly or Novo Nordisk? Continue Reading
This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) and contract manufacturer Resilience will invest $750 million to expand pharmaceutical production in the Cincinnati region, adding Lilly's KwikPen injectable device to Resilience's operations. Lilly shares are down 2.24% intraday. The expansion creates at least …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Eli Lilly (NYSE:LLY) has joined Illumina's Billion Cell Atlas alliance as a foundational participant. …
Resilience and Lilly expand strategic partnership first established in 2023 Investment will significantly increase U.S. production of Lilly's KwikPen® injectable device for diabetes and obesity medicines to meet growing patient demand 400 new high-skilled jobs to be created in the Cincinnati, Ohio region Coincides …
The market expects Eli Lilly (LLY) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might …
In the latest close session, Eli Lilly (LLY) was up +2.09% at $1,222.61. The stock outperformed the S&P 500, which registered a daily gain of 0.21%. On the other hand, the Dow registered a gain of 1.03%, and the technology-centric Nasdaq decreased by 0.22%. …
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Analysts have been lifting Eli Lilly price targets, with recent valuation work for the stock pointing to fair value of US$1,270.37 compared with …
Search by ticker symbol or company name and select a result to open its chart.